title: Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review.
abstract: Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults?
  
  
  
  There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, -3.7 to -2.0 points) and 1.6 points (95% CI, -3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.
authors.affiliation: Department of Dermatology & Academic Wound Healing, Institute of Infection & Immunity, Cardiff University, Wales.
authors.forename: John R
authors.initials: JR
authors.lastname: Ingram
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017497:Hidradenitis Suppurativa / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D000069285:Infliximab; D000068879:Adalimumab